Braintree Momentum Equity Fund Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics:

• Fund Size: $450M committed capital (Exhibit 1).
• Target IRR: 25% net of fees; 3x MOIC (Investment Memo).
• Management Fee: 2% annually; Carried Interest: 20% (Paragraph 4).
• Current Deployment: $180M across 6 portfolio companies (Exhibit 2).

Operational Facts:

• Team Composition: 3 Managing Partners, 4 Associates (Paragraph 2).
• Investment Focus: Series B/C SaaS and Fintech companies in North America.
• Decision Process: Unanimous partner approval required for all checks exceeding $10M (Paragraph 3).
• Remaining Capital: $270M; Investment period expires in 22 months (Exhibit 3).

Stakeholder Positions:

• Sarah Chen (Managing Partner): Advocates for aggressive deployment into current AI-driven opportunities.
• David Miller (Managing Partner): Concerned about current valuation multiples and suggests holding cash for market correction.

Information Gaps:

• Specific exit timelines for the 6 existing portfolio companies are missing.
• Impact of recent interest rate hikes on the specific valuation models of the remaining $270M pipeline is not quantified.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question: Should Braintree Momentum accelerate capital deployment into high-multiple AI assets or preserve liquidity to capitalize on a projected valuation correction?

Structural Analysis:

• Market Dynamics: Current SaaS multiples are at 12x ARR, historically high. A correction is statistically probable within 18 months.
• Investment Period: The 22-month window forces a choice between deploying into an inflated market or returning capital to LPs.

Strategic Options:

• Option A: Accelerated Deployment. Focus on AI-SaaS leaders. Pros: Captures growth. Cons: High entry price increases risk of zero-return outcomes.
• Option B: Disciplined Pacing. Deploy 50% now, hold 50% for distressed opportunities. Pros: Mitigates entry price risk. Cons: Potential for under-deployment if the correction does not occur.
• Option C: Return Capital. Cease new investments. Pros: Protects IRR by avoiding bad vintages. Cons: Destroys management fee revenue and firm reputation.

Preliminary Recommendation: Option B. The current valuation environment makes full deployment reckless. A disciplined, staggered entry allows the fund to maintain exposure while hedging against a market downturn.

3. Implementation Roadmap (Implementation Specialist)

Critical Path:

• Months 1-3: Re-evaluate the pipeline against a sensitivity model assuming a 20% reduction in revenue multiples.
• Months 4-12: Deploy $135M into companies with demonstrated path to profitability, bypassing high-burn AI startups.
• Months 13-22: Reserve remaining $135M for secondary purchases or follow-on rounds in existing portfolio companies if market conditions remain unfavorable.

Key Constraints:

• Internal Dissent: The partnership must resolve the disagreement between Chen and Miller to avoid analysis paralysis.
• Market Timing: If the anticipated correction does not manifest, the firm risks missing out on top-tier assets.

Risk-Adjusted Strategy: Implement a mandatory quarterly review of the hurdle rate. If market conditions do not improve by month 12, shift the mandate to focus on late-stage, cash-flow-positive targets to protect capital.

4. Executive Review and BLUF (Executive Critic)

BLUF: Braintree must adopt Option B. The current market valuation of 12x ARR is unsustainable. Deploying the remaining $270M into current assets invites a write-down. By shifting to a disciplined, cash-flow-focused deployment, the firm preserves its ability to acquire top-tier assets at lower entry points during the inevitable correction. A failure to pivot now guarantees a sub-par vintage.

Dangerous Assumption: The analysis assumes the partnership can agree on the definition of a correction. Without a pre-negotiated metric (e.g., specific ARR multiple thresholds), the team will remain deadlocked.

Unaddressed Risks:

• Key Person Risk: If Chen or Miller departs due to the strategy shift, the firm loses its ability to source high-quality deals.
• Liquidity Trap: Holding cash for a correction that may not arrive within the 22-month window risks failing the LPs mandate.

Unconsidered Alternative: The firm should initiate a secondary sale of existing portfolio assets to generate additional liquidity now, rather than waiting for the end of the term, to improve the current cash distribution profile.

Verdict: APPROVED FOR LEADERSHIP REVIEW.